Evidence map›Paper›PMID 41656191›Full record

ArticleBMC cancer2026

Updated incidence of EGFR mutation in Middle Eastern patients with non-small cell lung cancer: a 7-year study in a Lebanese institution.

Hampig Raphael Kourie, Charbel Farhat, Joseph Zouein, Alain Chebly, Fouad Noujeim, Moussa Riachy, Georges Dabar, Carine Harmouche, Bassem Haber, Zeina Aoun Bacha and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hampig Raphael KourieHematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon. Hampig.kourie@usj.edu.lb.
Charbel FarhatHematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Joseph ZoueinHematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Alain CheblyCenter Jacques Loiselet for Medical Genetics and Genomics (CGGM), Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Fouad NoujeimHematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Moussa RiachyPneumology and Critical Care Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Georges DabarPneumology and Critical Care Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Carine HarmouchePneumology and Critical Care Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Bassem HaberPneumology and Critical Care Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Zeina Aoun BachaPneumology and Critical Care Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Joseph KattanHematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Fady NasrHematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Georges ChahineHematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Marwan GhosnHematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Vivianne Trak-SmayraPathology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Fadi ElKarakHematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Carole KesrouaniPathology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aims to update the mutational status of EGFR in non-small cell carcinoma (NSCLC), to analyze the spectrum of mutations found, and describe rare mutations in the Lebanese population.

methodsIn this retrospective study, patients diagnosed with NSCLC between 2016 and 2023 who underwent EGFR mutation testing were included. EGFR mutations from 2016 to 2019 were analyzed using real-time PCR on the Rotor-Gene Q platform, while those from 2019 to 2023 were analyzed using real-time PCR with the Idylla system.

results332 patients of which 211 (63.3%) men and 121 (36.7%) women were included. Mean age was 65.7 years. Adenocarcinoma was the main histological subtype. Additionally, 16.3% of patients had an EGFR mutation: 50% had a deletion on exon 19, 37% an L858R mutation, 4% a G719/C/S mutation, 4% a T790M mutation alone, 2% an L861Q mutation alone, and 2% a S768I mutation alone. A statistically significant difference (p < 0.0285) was found between the positivity rates of the two EGFR mutation detection techniques, favoring the Idylla technique.

conclusionWe confirmed the variation in the incidence of EGFR mutated NSCLC between Lebanon and the region. Mutational frequencies remain similar, with the highest frequencies being for exon 19 and 21 mutations.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMutationAdultAgedAged, 80 and overErbB ReceptorsExonsFemaleHumansIncidenceLebanonMaleMiddle AgedMiddle Eastern PeopleRetrospective StudiesEGFR protein, humanErbB ReceptorsEpidermal growth factor receptorIncidenceLebanonMutationNon-small cell lung carcinoma

Identifiers

PMID41656191
PMCPMC12990391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.